Drugs in MeSH Category Bronchodilator Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	BRICANYL	terbutaline sulfate	INJECTABLE;INJECTION	017466-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ortho Mcneil Pharm	THEOPHYL-225	theophylline	TABLET;ORAL	084726-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes	8,776,795*PED				Y
Kaleo Inc	AUVI-Q	epinephrine	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	201739-002	Aug 10, 2012	BX	RX	Yes	Yes	8,021,344		Y
Ritedose Corp	FORMOTEROL FUMARATE	formoterol fumarate	SOLUTION;INHALATION	216486-001	Nov 25, 2022	AN	RX	No	No

Market Dynamics and Patent Landscape for Bronchodilator Agents in NLM MeSH Class

Last updated: July 28, 2026

The Bronchodilator Agents market is a multi-asset category dominated by inhaled long-acting bronchodilators (LABA and LAMA), fixed-dose LABA/LAMA combinations, and LABA/ICS regimens. Patent cliffs concentrate around platform expiries for specific inhalers and salts, plus secondary formulation and device patents that extend brand leverage. Competitive pressure is driven by: (1) FDA generics and authorized inhaler/device copycats, (2) “next-gen” reformulations and co-suspensions, and (3) new entrants using Paragraph IV challenges where Orange Book coverage is weakest or lags device-related exclusivities.

Scope note (MeSH mapping): MeSH “Bronchodilator Agents” is broad. The practical patent and market dynamics are most directly shaped by the major FDA inhaled bronchodilator active ingredients and their combination products that carry the largest prescription and payer exposure.

---

What patent estate protects inhaled LABA and LAMA bronchodilator agents most?

The largest patent estates in this class typically stack four layers: composition of matter (CoM) salts/polymorphs, formulation (particle size, co-suspension, pH/osmolality), method-of-use (COPD and/or asthma maintenance, exacerbation reduction, specific dosing schedules), and device/inhalation system (metering, priming, plume geometry, dose uniformity). Inhaled drug patents frequently extend commercial life even after primary CoM expiry via reformulation patents that secure “new” Orange Book listings for additional strengths, combination ratios, or delivery systems.

Typical patent categories that block generic substitution

1. CoM for active ingredient or salt
   • Example patterns include protection for indacaterol/glycopyrronium salts, tiotropium forms, formoterol forms, salmeterol forms, and umeclidinium.
2. Formulation patents
   • Protective claims often target dry powder particle engineering, water content targets for stability, or suspending agents for nebulized solutions.
3. Method-of-use patents
   • Use claims commonly cover “maintenance treatment” of COPD or asthma, sometimes with specific inhalation schedules.
4. Device and delivery patents
   • Metering valve geometry, dose counter algorithms, and inhaler mechanics drive non-infringing design-around risk.
5. Orange Book coverage by multiple NDA/ANDA components
   • Fixed-dose combinations often create multiple parallel Orange Book records (single active plus combination) that increase the probability that at least one patent is still in force.

---

How do exclusivity timelines work for bronchodilator agents: Orange Book exclusivity vs patent term?

Featured-snippet answer: exclusivity is time-limited and listed separately from patents. Brands may lose “exclusivity” but still block generics if any Orange Book patent remains in force and is not cleared through noninfringing, invalidation, or settlement terms.

Key time mechanics

• Patent term runs from the earliest effective filing date (subject to adjustments) and ends per patent.
• Orphan drug exclusivity rarely applies in this class for major bronchodilators.
• New chemical entity (NCE) and new formulation exclusivities can affect launch timing for specific NDAs or specific active moieties and sometimes for certain new strengths or delivery forms.
• LTE (limited by) secondary patenting: Even when primary CoM expires, formulation and device patents can sustain Orange Book coverage.

Where cliffs concentrate

• LABA/LAMA combinations face cliff risk when both component CoMs plus the combination-specific formulation/device patents reach end-of-term or are narrowed enough to permit entry.
• LABA/ICS estates can remain protected longer because inhaled corticosteroid combinations expand method-of-use and formulation claims.

---

What patents cover fixed-dose LABA/LAMA combinations most effectively?

Fixed-dose combinations are where brands most often lock down launch windows. The patent strategy typically covers:

• Combination ratios (drug amounts per dose)
• Co-formulation particle characteristics in dry powder or stability windows in solution
• Inhaler compatibility (device-specific performance claims)
• Clinical regimen claims that tie dosing schedule to outcomes (symptom control, exacerbation prevention)

Common claim themes in Orange Book listings

• “A pharmaceutical composition comprising [LABA] and [LAMA] in a specified mass ratio.”
• “A method of treating COPD comprising administering the composition at a defined dosing frequency.”
• “A stable dry powder formulation with controlled moisture content and particle size distribution.”
• “A device system configured to deliver a target emitted dose.”

---

Which bronchodilator agents have the strongest patent estates by market leverage?

High-leverage estates usually correlate with:

• Long-acting monotherapies with broad COPD share,
• Combination products with payer formularies,
• Delivery systems with entrenched device switching costs.

Market leverage pattern

• Monotherapies: protect ongoing demand but have fewer “lock-in” opportunities than combinations.
• Combinations: carry more Orange Book entries and higher risk for generic entry because ANDA Paragraph IV challengers must clear multiple patents across multiple actives and often the delivery system.

---

How strong is patent coverage for LAMA monotherapies compared with LABA monotherapies?

Featured-snippet answer: LAMA estates often show heavier formulation and device-specific secondary protection, while LABA estates more often rely on CoM for salts and method-of-use for COPD maintenance. Real-world strength differs by active ingredient and whether combination reformulations added new Orange Book listings.

Design-around pressure

• LAMA inhalers often require consistent emitted dose and moisture stability, which invites formulation-related patent coverage.
• LABA products may have multiple dosage strength Orange Book listings; the “strength-by-strength” patent status can change generic timing.

---

Which generic entry risks exist for inhaled bronchodilator products under Paragraph IV?

Entry risk rises when at least one of the following is true:

• An Orange Book patent is not listed for the specific strength/formulation the generic wants to launch.
• A patent is easy to design around through alternative excipients or particle engineering that avoids claim scope.
• Settlement removes the “remaining” Orange Book patents from effective blocking.

Entry risk is lower when:

• Multiple patents remain listed across drug product and device.
• Method-of-use patents remain unchallenged and are not effectively carved out by label changes.
• Device patents require noninfringing inhaler redesign or create combination of clinical and device constraints.

Litigation pattern in bronchodilators

Paragraph IV cases commonly turn on:

• claim construction for composition/formulation,
• noninfringement via alternative excipient and particle distribution,
• obviousness arguments around known prior art inhaled formulations.

---

What patent litigation affects bronchodilator agents the most in the US?

Featured-snippet answer: litigation most often targets core formulation and method-of-use patents and then settles into “at-risk” licensing where the generic delays launch until certain patents expire or is allowed to launch with carve-outs tied to label language.

How settlements typically shape launch

• Staggered entry by strength or dosing form.
• Label carve-outs tied to method-of-use claims.
• Amended labeling reflecting non-infringement design.
• Trigger-based early entry tied to FDA approval events.

---

What is the Orange Book status of major inhaled bronchodilator products?

A product-by-product Orange Book status requires current listing extraction per active, dosage form, and NDA. Without that listing-level dataset, only the structural rule applies: generic timing is governed by the latest in-force Orange Book patents for the exact drug product and strength, plus any relevant exclusivity.

Operational implication: within MeSH “Bronchodilator Agents,” investors and licensing teams should treat each NDA (including each strength and delivery system) as its own blocking set, not as a single expiration date for the active ingredient.

---

How do device and inhalation-system patents extend brand exclusivity for inhaled bronchodilators?

Device patents are a key friction point because:

• Generic companies can be forced to adopt a different delivery system, which can trigger formulation/device mismatch risk.
• Even when drug composition is cleared, device performance and dose uniformity must meet FDA standards, which can cause additional development time.
• In some estates, device and formulation patents are “co-owned” by different entities, requiring multi-party licensing.

Device claim clusters

• metering mechanism,
• dose counter and alignment,
• inhalation-flow-dependent aerosolization features,
• priming requirements and plume geometry.

---

How does FDA regulatory pathway choice affect generic or biosimilar risk for bronchodilators?

Bronchodilator agents in this class are overwhelmingly small molecules delivered by inhalation, so the dominant risk is ANDA-to-505(j) generics, not biosimilarity.

Regulatory pathway dynamics

• ANDAs must prove pharmaceutical equivalence and bioequivalence (or demonstrate acceptable bridging for inhaled products under FDA standards).
• Device changes can affect regulatory review because emitted dose and particle characteristics influence clinical equivalence.
• Carve-out labeling can reduce method-of-use infringement exposure but may not fully align with FDA approval labeling.

---

Which commercial scenarios drive the biggest patent-to-revenue sensitivity in bronchodilators?

Revenue sensitivity is highest when the brand holds:

• a dominant place in COPD step-therapy pathways,
• payer-preferred formulary status,
• and a “combination advantage” over monotherapies.

High-impact entry scenarios

1. Combination product loss
   • Fixed-dose LABA/LAMA or LABA/ICS often substitutes for two separate inhalers.
2. Strength-specific entry
   • Launch of one strength can pressure pricing while the rest remain protected.
3. Device-switching substitution
   • A generic with a different inhaler design can still capture share if prescriber switching is manageable and pharmacy access improves.

---

How does the patent landscape differ between COPD bronchodilators and asthma bronchodilators?

Featured-snippet answer: COPD bronchodilators lean on long-acting maintenance method-of-use and formulation stability patents for chronic use. Asthma regimens often have more complex label structures due to combination therapy (LABA/ICS) and background therapy interactions, which increases method-of-use and regimen-specific patent coverage.

Implication for generics

• COPD maintenance claims may be easier to carve out with label language if the generic targets acute or alternative therapeutic indications. Asthma labeling constraints are often narrower and can make carve-outs harder without affecting the approved indication.

---

How do LABA/ICS estates compare with LABA/LAMA estates in patent density?

Featured-snippet answer: LABA/ICS estates frequently show higher patent density because the inhaled corticosteroid adds additional formulation, device compatibility, and regimen method-of-use layers.

Why density is higher

• combination stability,
• dosing synchronization,
• safety and efficacy data support for label-specific claims,
• device plume and deposition requirements for two pharmacologic classes.

---

Key takeaways

• Bronchodilator patent estates are layered: CoM plus formulation, method-of-use, and device/inhalation-system protection.
• Market exclusivity is not the same as patent status; loss of one form of exclusivity does not permit generic entry if Orange Book patents remain in force.
• Fixed-dose combinations (LABA/LAMA and LABA/ICS) carry the highest blocking set because they stack multiple actives and often multiple delivery-system constraints.
• Paragraph IV generic entry risk hinges on whether Orange Book patents remain in force for the exact strength and delivery system the generic wants to market, plus the strength of claim scope for formulation and method-of-use patents.
• Device and inhaler-system patents can extend effective exclusivity by forcing non-trivial redesign even where drug composition is cleared.

---

FAQs

1. Which patent types most commonly delay generic inhaled LABA/LAMA launch in the US?
2. How do label carve-outs interact with method-of-use patents for COPD maintenance inhalers?
3. Do device patents block generic entry even when the drug composition is noninfringing?
4. What Orange Book listing patterns most often create strength-by-strength launch timing in bronchodilators?
5. How do settlement agreements typically structure early generic entry for inhaled bronchodilators?

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Drug Approval Reports. https://www.accessdata.fda.gov/drugsatfda_docs/label/
3. National Library of Medicine. (n.d.). MeSH: Bronchodilator Agents. https://meshb.nlm.nih.gov/
4. U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDA). https://www.fda.gov/drugs/abbreviated-new-drug-application-anda